1 month ago
On August 5, Vaxcyte (NASDAQ:PCVX) reported second-quarter results that read less like a snapshot of today and more like a countdown to a verdict. The clinical-stage vaccine maker has no product on the market yet, but its three late-stage trials for its lead pneumococcal candidate are now fully enrolled, with the first major readout due before year-end. Add a net loss that nearly doubled and a boardroom that just brought in two vaccine-industry veterans, and you have a company betting its near-term story on data still to come.
Vaxcyte's three Phase 3 studies of VAX-31, its next-generation pneumococcal conjugate vaccine, have dosed 6,191 adults combined, with roughly 3,500 of them receiving the actual candidate. The largest, OPUS-1, put 4,049 participants through head-to-head comparisons against Prevnar 20 and Capvaxive, the two shots VAX-31 needs to beat to earn a spot in the standard vaccination schedule. Data on safety, tolerability, and immune response from that trial are due in the fourth quarter of 2026, with results from OPUS-2 and OPUS-3 following in the first half of 2027.
A separate Phase 2 study testing VAX-31 in infants, covering both the primary immunization series and a booster dose, is on a similar timeline. In June, Vaxcyte also dosed the first participants in a Phase 1 study of VAX-A1, aimed at preventing disease from Group A Streptococcus, with topline data expected in the second half of 2027. As of June 30, cash and investments stood at $2.5 billion, up from $2.44 billion at the end of 2025, and the board added Dr. Moncef Slaoui, previously chief scientific advisor to Operation Warp Speed and a three-decade GSK veteran, alongside Dr. John Markels, the former president of Merck's global vaccines business.
None of that pipeline progress comes cheap. Vaxcyte's net loss for the quarter ended June 30 was $284.3 million, up from $166.6 million in the same period a year earlier, and the increase shows up on both sides of the ledger. R&D spending rose to $267.9 million from $194.2 million, driven by manufacturing work to prepare for a possible launch and by the cost of running three simultaneous Phase 3 trials at once. G&A expenses climbed too, to $34.9 million from $32 million, largely from adding headcount.
Because Vaxcyte has no approved product generating sales, every one of those dollars comes straight off the balance sheet. The calendar adds pressure of its own: even a clean OPUS-1 readout in the fourth quarter of 2026 still leaves the OPUS-2 and OPUS-3 results, plus a required manufacturing consistency study, sitting in the first half of 2027, pushing any license application and launch well beyond that. The newer VAX-A1 program is earlier still, with its second stage contingent on a safety board signing off on the first.
#phase
Vaxcyte's three Phase 3 studies of VAX-31, its next-generation pneumococcal conjugate vaccine, have dosed 6,191 adults combined, with roughly 3,500 of them receiving the actual candidate. The largest, OPUS-1, put 4,049 participants through head-to-head comparisons against Prevnar 20 and Capvaxive, the two shots VAX-31 needs to beat to earn a spot in the standard vaccination schedule. Data on safety, tolerability, and immune response from that trial are due in the fourth quarter of 2026, with results from OPUS-2 and OPUS-3 following in the first half of 2027.
A separate Phase 2 study testing VAX-31 in infants, covering both the primary immunization series and a booster dose, is on a similar timeline. In June, Vaxcyte also dosed the first participants in a Phase 1 study of VAX-A1, aimed at preventing disease from Group A Streptococcus, with topline data expected in the second half of 2027. As of June 30, cash and investments stood at $2.5 billion, up from $2.44 billion at the end of 2025, and the board added Dr. Moncef Slaoui, previously chief scientific advisor to Operation Warp Speed and a three-decade GSK veteran, alongside Dr. John Markels, the former president of Merck's global vaccines business.
None of that pipeline progress comes cheap. Vaxcyte's net loss for the quarter ended June 30 was $284.3 million, up from $166.6 million in the same period a year earlier, and the increase shows up on both sides of the ledger. R&D spending rose to $267.9 million from $194.2 million, driven by manufacturing work to prepare for a possible launch and by the cost of running three simultaneous Phase 3 trials at once. G&A expenses climbed too, to $34.9 million from $32 million, largely from adding headcount.
Because Vaxcyte has no approved product generating sales, every one of those dollars comes straight off the balance sheet. The calendar adds pressure of its own: even a clean OPUS-1 readout in the fourth quarter of 2026 still leaves the OPUS-2 and OPUS-3 results, plus a required manufacturing consistency study, sitting in the first half of 2027, pushing any license application and launch well beyond that. The newer VAX-A1 program is earlier still, with its second stage contingent on a safety board signing off on the first.
#phase
1 month ago
On August 5, Vaxcyte (NASDAQ:PCVX) reported second-quarter results that read less like a snapshot of today and more like a countdown to a verdict. The clinical-stage vaccine maker has no product on the market yet, but its three late-stage trials for its lead pneumococcal candidate are now fully enrolled, with the first major readout due before year-end. Add a net loss that nearly doubled and a boardroom that just brought in two vaccine-industry veterans, and you have a company betting its near-term story on data still to come.
Vaxcyte's three Phase 3 studies of VAX-31, its next-generation pneumococcal conjugate vaccine, have dosed 6,191 adults combined, with roughly 3,500 of them receiving the actual candidate. The largest, OPUS-1, put 4,049 participants through head-to-head comparisons against Prevnar 20 and Capvaxive, the two shots VAX-31 needs to beat to earn a spot in the standard vaccination schedule. Data on safety, tolerability, and immune response from that trial are due in the fourth quarter of 2026, with results from OPUS-2 and OPUS-3 following in the first half of 2027.
A separate Phase 2 study testing VAX-31 in infants, covering both the primary immunization series and a booster dose, is on a similar timeline. In June, Vaxcyte also dosed the first participants in a Phase 1 study of VAX-A1, aimed at preventing disease from Group A Streptococcus, with topline data expected in the second half of 2027. As of June 30, cash and investments stood at $2.5 billion, up from $2.44 billion at the end of 2025, and the board added Dr. Moncef Slaoui, previously chief scientific advisor to Operation Warp Speed and a three-decade GSK veteran, alongside Dr. John Markels, the former president of Merck's global vaccines business.
None of that pipeline progress comes cheap. Vaxcyte's net loss for the quarter ended June 30 was $284.3 million, up from $166.6 million in the same period a year earlier, and the increase shows up on both sides of the ledger. R&D spending rose to $267.9 million from $194.2 million, driven by manufacturing work to prepare for a possible launch and by the cost of running three simultaneous Phase 3 trials at once. G&A expenses climbed too, to $34.9 million from $32 million, largely from adding headcount.
Because Vaxcyte has no approved product generating sales, every one of those dollars comes straight off the balance sheet. The calendar adds pressure of its own: even a clean OPUS-1 readout in the fourth quarter of 2026 still leaves the OPUS-2 and OPUS-3 results, plus a required manufacturing consistency study, sitting in the first half of 2027, pushing any license application and launch well beyond that. The newer VAX-A1 program is earlier still, with its second stage contingent on a safety board signing off on the first.
#opus #data
Vaxcyte's three Phase 3 studies of VAX-31, its next-generation pneumococcal conjugate vaccine, have dosed 6,191 adults combined, with roughly 3,500 of them receiving the actual candidate. The largest, OPUS-1, put 4,049 participants through head-to-head comparisons against Prevnar 20 and Capvaxive, the two shots VAX-31 needs to beat to earn a spot in the standard vaccination schedule. Data on safety, tolerability, and immune response from that trial are due in the fourth quarter of 2026, with results from OPUS-2 and OPUS-3 following in the first half of 2027.
A separate Phase 2 study testing VAX-31 in infants, covering both the primary immunization series and a booster dose, is on a similar timeline. In June, Vaxcyte also dosed the first participants in a Phase 1 study of VAX-A1, aimed at preventing disease from Group A Streptococcus, with topline data expected in the second half of 2027. As of June 30, cash and investments stood at $2.5 billion, up from $2.44 billion at the end of 2025, and the board added Dr. Moncef Slaoui, previously chief scientific advisor to Operation Warp Speed and a three-decade GSK veteran, alongside Dr. John Markels, the former president of Merck's global vaccines business.
None of that pipeline progress comes cheap. Vaxcyte's net loss for the quarter ended June 30 was $284.3 million, up from $166.6 million in the same period a year earlier, and the increase shows up on both sides of the ledger. R&D spending rose to $267.9 million from $194.2 million, driven by manufacturing work to prepare for a possible launch and by the cost of running three simultaneous Phase 3 trials at once. G&A expenses climbed too, to $34.9 million from $32 million, largely from adding headcount.
Because Vaxcyte has no approved product generating sales, every one of those dollars comes straight off the balance sheet. The calendar adds pressure of its own: even a clean OPUS-1 readout in the fourth quarter of 2026 still leaves the OPUS-2 and OPUS-3 results, plus a required manufacturing consistency study, sitting in the first half of 2027, pushing any license application and launch well beyond that. The newer VAX-A1 program is earlier still, with its second stage contingent on a safety board signing off on the first.
#opus #data
1 month ago
After years of chasing his dream of becoming a professional race car driver, Frankie Muniz finally has a victory to celebrate.
Muniz earned the first professional racing win of his career Friday at Road America, taking the Am class victory in the Pirelli GT4 America Series alongside co-driver Tyler Stone. The duo drove the No. 30 TechSport Racing Ford Mustang GT4 to the historic result.
The victory was a major milestone for Muniz, who has spent years building a second career in motorsports after becoming famous as an actor. While Muniz has competed in several different racing series, including NASCAR, a professional victory had remained out of reach.
That finally changed at one of his favorite tracks.
Stone made the decisive move late in the race, taking the Am class lead with about five minutes remaining. He held off the competition to secure the win for the No. 30 Mustang, giving Muniz and the TechSport Racing team their first victory of the season.
#victory #professional #series
Muniz earned the first professional racing win of his career Friday at Road America, taking the Am class victory in the Pirelli GT4 America Series alongside co-driver Tyler Stone. The duo drove the No. 30 TechSport Racing Ford Mustang GT4 to the historic result.
The victory was a major milestone for Muniz, who has spent years building a second career in motorsports after becoming famous as an actor. While Muniz has competed in several different racing series, including NASCAR, a professional victory had remained out of reach.
That finally changed at one of his favorite tracks.
Stone made the decisive move late in the race, taking the Am class lead with about five minutes remaining. He held off the competition to secure the win for the No. 30 Mustang, giving Muniz and the TechSport Racing team their first victory of the season.
#victory #professional #series
2 months ago
Craven Cottage stages a first-ever competitive meeting between Fulham and AFC Wimbledon on Thursday, with a place in the Carabao Cup third round at stake.
Fulham enter off the back of a narrow 2-3 defeat to Chelsea on the Premier League's opening weekend, Alvaro Arbeloa's first game in charge, while Wimbledon have gone six matches without a win across all competitions and are yet to score in League One this season.
Wimbledon reached this stage only after Callum Maycock's dramatic 97th-minute equaliser forced a penalty shootout against Newport County, which the Dons went on to win. Fulham, whose 146-year history has never produced a major trophy, reached the Carabao Cup quarter-finals last season and will see this competition as a realistic route to silverware. Steven Sessegnon, who began his career at Fulham before moving on, could line up for Wimbledon against his former club.
Date: Thursday, 27 August 2026Kick-off: 20:00 BSTVenue: Craven Cottage
Captain Tom Cairney remains sidelined with a knee injury and is not expected back until later in the autumn. Joachim Andersen is available again having served the final match of a three-game suspension against Chelsea, though Arbeloa may still use the tie to rest him. Several substitutes from the Chelsea game, including Ryan Sessegnon, Rodrigo Muniz, Harrison Reed and Shea Charles, are pushing for starts.
#carabao
Fulham enter off the back of a narrow 2-3 defeat to Chelsea on the Premier League's opening weekend, Alvaro Arbeloa's first game in charge, while Wimbledon have gone six matches without a win across all competitions and are yet to score in League One this season.
Wimbledon reached this stage only after Callum Maycock's dramatic 97th-minute equaliser forced a penalty shootout against Newport County, which the Dons went on to win. Fulham, whose 146-year history has never produced a major trophy, reached the Carabao Cup quarter-finals last season and will see this competition as a realistic route to silverware. Steven Sessegnon, who began his career at Fulham before moving on, could line up for Wimbledon against his former club.
Date: Thursday, 27 August 2026Kick-off: 20:00 BSTVenue: Craven Cottage
Captain Tom Cairney remains sidelined with a knee injury and is not expected back until later in the autumn. Joachim Andersen is available again having served the final match of a three-game suspension against Chelsea, though Arbeloa may still use the tie to rest him. Several substitutes from the Chelsea game, including Ryan Sessegnon, Rodrigo Muniz, Harrison Reed and Shea Charles, are pushing for starts.
#carabao
2 months ago
Frankie Muniz opened up about some serious heartbreak nearly two months after announcing his divorce from wife Paige Price.
The Malcolm in the Middle alum, 40, revealed that he was struggling in a cryptic post shared on X on Wednesday, August 26.
"Am I naive to say that I didn't know that having a broken heart actually meant your heart physically aches," Muniz wrote. "I'd rather break my back again."
The Big Fat Liar star was likely referring to a serious 2009 race car crash that left him with a broken back and multiple other broken bones.
While he didn't reveal what prompted the message, it comes less than two months after he and Price, 34, announced they were ending their marriage after nearly seven years following a private separation.
#muniz #heart
The Malcolm in the Middle alum, 40, revealed that he was struggling in a cryptic post shared on X on Wednesday, August 26.
"Am I naive to say that I didn't know that having a broken heart actually meant your heart physically aches," Muniz wrote. "I'd rather break my back again."
The Big Fat Liar star was likely referring to a serious 2009 race car crash that left him with a broken back and multiple other broken bones.
While he didn't reveal what prompted the message, it comes less than two months after he and Price, 34, announced they were ending their marriage after nearly seven years following a private separation.
#muniz #heart
2 months ago
Frankie Muniz decided to not compete in Saturday's NASCAR Craftsman Truck Series race at New Hampshire. His teammate Luke Baldwin, who failed to qualify for the event on Friday, replaced Muniz in the No. 33 Team Reaume Ford.
Muniz, actor-turned-NASCAR driver most known for his role as Malcolm in Malcolm in the Middle, believed Baldwin being behind the wheel would be the best opportunity for the team to run well.
Because Baldwin failed to qualify, Muniz wanted to give his younger teammate an opportunity to race.
In a statement released by Team Reaume, Muniz explained his decision to step aside for Saturday's Team EJP 175.
Muniz praised Baldwin's talent and said the 20-year-old did everything in his power to qualify for the event. Unfortunately, it did not work out. The 40-year-old did not want Baldwin to be on the sidelines, however, and decided to give up his spot for Saturday's race.
#muniz #baldwin #race #reaume
Muniz, actor-turned-NASCAR driver most known for his role as Malcolm in Malcolm in the Middle, believed Baldwin being behind the wheel would be the best opportunity for the team to run well.
Because Baldwin failed to qualify, Muniz wanted to give his younger teammate an opportunity to race.
In a statement released by Team Reaume, Muniz explained his decision to step aside for Saturday's Team EJP 175.
Muniz praised Baldwin's talent and said the 20-year-old did everything in his power to qualify for the event. Unfortunately, it did not work out. The 40-year-old did not want Baldwin to be on the sidelines, however, and decided to give up his spot for Saturday's race.
#muniz #baldwin #race #reaume
2 months ago
There aren't many teammates who would do what Frankie Muniz decided to do on Friday. After qualifying for the NASCAR Craftsman Truck Series (NCTS) race at New Hampshire Motor Speedway, Team Reaume's Luke Baldwin and the No. 2 Ford were among the five DNQs.
Muniz, who is a full-time driver in the Truck Series in the No. 33, was set to start at the very back of the field in 36th for Saturday's race.
However, the actor-turned-racer made the decision to willingly give up his seat for the race, allowing Baldwin to take over the No. 33 for this weekend's NCTS event.
"Luke is one of the most talented young drivers in this garage, and this team has two trucks here this weekend," said Muniz in a release from the team. "He came here ready to race and did everything he could. Sitting him out when we have a qualified truck that can put him in the field doesn't make sense for anyone. I'm giving up my seat because I believe it gives the 33 team the best chance to compete for the most available points this weekend. Luke's speed and his ability to run up front when he gets a clean run is what this organization needs right now. I'll be in the pits cheering him on."
Team owner Josh Reaume praised Muniz for the decision, saying: "Frankie didn't hesitate. That's the kind of teammate and person he is. "Luke has shown time and time again that he can extract everything from our equipment. With the regular season ending Saturday and owner points still on the table, this move puts our strongest available driver in the No. 33 for the 175-lap race. We appreciate Frankie's selflessness and look forward to seeing Luke behind the wheel."
#muniz #LUKE #ncts
Muniz, who is a full-time driver in the Truck Series in the No. 33, was set to start at the very back of the field in 36th for Saturday's race.
However, the actor-turned-racer made the decision to willingly give up his seat for the race, allowing Baldwin to take over the No. 33 for this weekend's NCTS event.
"Luke is one of the most talented young drivers in this garage, and this team has two trucks here this weekend," said Muniz in a release from the team. "He came here ready to race and did everything he could. Sitting him out when we have a qualified truck that can put him in the field doesn't make sense for anyone. I'm giving up my seat because I believe it gives the 33 team the best chance to compete for the most available points this weekend. Luke's speed and his ability to run up front when he gets a clean run is what this organization needs right now. I'll be in the pits cheering him on."
Team owner Josh Reaume praised Muniz for the decision, saying: "Frankie didn't hesitate. That's the kind of teammate and person he is. "Luke has shown time and time again that he can extract everything from our equipment. With the regular season ending Saturday and owner points still on the table, this move puts our strongest available driver in the No. 33 for the 175-lap race. We appreciate Frankie's selflessness and look forward to seeing Luke behind the wheel."
#muniz #LUKE #ncts
2 months ago
Dayanara Torres had another major family milestone to celebrate this weekend as her youngest son, Ryan Muñiz, officially turned 23. The former Miss Universe marked Ryan's birthday on August 16 with a loving message and a family celebration that brought together some of the people closest to him. Ryan, whom Torres shares with ex-husband Marc Anthony, is the younger brother of Cristian Muñiz, 25.
For Torres, who regularly shares her pride in her two sons, Ryan's latest birthday came during an especially exciting chapter in his life. The 23-year-old has been exploring both music and modeling and recently made his runway debut, adding another accomplishment to an already creative résumé.
Dayanara Torres celebrates son Ryan Muñiz's 23rd birthday with a family gathering, a loving tribute and a milestone moment in his rising career. (@ xdamn_ramx)
Torres celebrated her youngest son on social media with a video offering followers a glimpse at his birthday festivities. "Happy Birthday Ryan. Te Amo," she wrote, adding, "¡Qué dicha tenerte conmigo y poderte celebrar!" The Puerto Rican beauty queen also affectionately described Ryan as her "cómplice," "guardaespaldas" and roommate, making it clear that their relationship has grown into a close friendship now that her son is an adult.
You may also like
#ryan #birthday #milestone
For Torres, who regularly shares her pride in her two sons, Ryan's latest birthday came during an especially exciting chapter in his life. The 23-year-old has been exploring both music and modeling and recently made his runway debut, adding another accomplishment to an already creative résumé.
Dayanara Torres celebrates son Ryan Muñiz's 23rd birthday with a family gathering, a loving tribute and a milestone moment in his rising career. (@ xdamn_ramx)
Torres celebrated her youngest son on social media with a video offering followers a glimpse at his birthday festivities. "Happy Birthday Ryan. Te Amo," she wrote, adding, "¡Qué dicha tenerte conmigo y poderte celebrar!" The Puerto Rican beauty queen also affectionately described Ryan as her "cómplice," "guardaespaldas" and roommate, making it clear that their relationship has grown into a close friendship now that her son is an adult.
You may also like
#ryan #birthday #milestone
2 months ago
Spire Motorsports will lead the NASCAR Truck Series starting lineup for the race at Richmond Raceway in July. Shane van Gisbergen won the pole for the 2026 Black's Tire 250 at Richmond this weekend. Kadne Honeycutt will join van Gisbergen on the front row for Friday night's event. It is van Gisbergen's first pole position of the 2026 Truck Series season.
Chandler Smith and Grant Enfinger will follow the two drivers on the second row. Most notably, Daniel Hemric, Jake Garcia, Tanner Gray, Mini Tyrell, Kris Wright, Elliott Salder, Frankie Muniz, and Dystany Spurlock all start 20th or worse for Friday's event.
The full NASCAR Truck Series starting lineup at Richmond in August 2026 is below!
No. 7 Shane van Gisbergen
No. 11 Kaden Honeycutt
#shane #honeycutt #lineup
Chandler Smith and Grant Enfinger will follow the two drivers on the second row. Most notably, Daniel Hemric, Jake Garcia, Tanner Gray, Mini Tyrell, Kris Wright, Elliott Salder, Frankie Muniz, and Dystany Spurlock all start 20th or worse for Friday's event.
The full NASCAR Truck Series starting lineup at Richmond in August 2026 is below!
No. 7 Shane van Gisbergen
No. 11 Kaden Honeycutt
#shane #honeycutt #lineup
3 months ago
Front Row Motorsports will lead the NASCAR Truck Series starting lineup for the race at Lucas Oil Raceway in July. Layne Riggs won the pole for the 2026 TSport 200 at Lucas Oil this weekend. Chandler Smith will join Riggs on the front row for Friday night's event. It is Riggs' third pole position of the 2026 Truck Series season.
Nick Sanchez and Christian Eckes will follow the two drivers on the second row. Most notably, Ben Rhodes, Harrison Burton, Justin Haley, Conor Daly, Toni Breidinger, and Frankie Muniz all start 20th or worse for Friday's event. Justin Carroll and Jonathan Shafer missed the event.
The full NASCAR Truck Series starting lineup at Lucas Oil in July 2026 is below!
No. 34 Layne Riggs
No. 38 Chandler Smith
#riggs
Nick Sanchez and Christian Eckes will follow the two drivers on the second row. Most notably, Ben Rhodes, Harrison Burton, Justin Haley, Conor Daly, Toni Breidinger, and Frankie Muniz all start 20th or worse for Friday's event. Justin Carroll and Jonathan Shafer missed the event.
The full NASCAR Truck Series starting lineup at Lucas Oil in July 2026 is below!
No. 34 Layne Riggs
No. 38 Chandler Smith
#riggs
3 months ago
Frankie Muniz and his wife, Paige Price Muniz, announced that they are ending their marriage after seven years. While the news came as a surprise to many fans, some focused on how the actor chose to share the update.
Some online users criticized the "Malcolm in the Middle" star for the video that accompanied the announcement, in which he was seen joyfully dancing with Paige and their young son. Paige has responded to the public criticism, noting how cruel people can be while defending Muniz's post.
On July 1, actor and professional racing driver Frankie Muniz took to social media to share an update about his personal life. Muniz said that after a period of separation from his wife, Paige Price Muniz, they have decided to push forward with a divorce.
Muniz posted a video of himself and Paige dancing enthusiastically to the lively song "Check Yes, Juliet" by We The Kings. Midway through the video, their son runs in to join the dance party.
Critics commented on the video, with some saying that it was "in poor taste." Others criticized the couple for "celebrating" their divorce. "Divorce with children should never be celebrated," one said. Another noted, "Hardly a reason to celebrate when there are children involved."
Some online users criticized the "Malcolm in the Middle" star for the video that accompanied the announcement, in which he was seen joyfully dancing with Paige and their young son. Paige has responded to the public criticism, noting how cruel people can be while defending Muniz's post.
On July 1, actor and professional racing driver Frankie Muniz took to social media to share an update about his personal life. Muniz said that after a period of separation from his wife, Paige Price Muniz, they have decided to push forward with a divorce.
Muniz posted a video of himself and Paige dancing enthusiastically to the lively song "Check Yes, Juliet" by We The Kings. Midway through the video, their son runs in to join the dance party.
Critics commented on the video, with some saying that it was "in poor taste." Others criticized the couple for "celebrating" their divorce. "Divorce with children should never be celebrated," one said. Another noted, "Hardly a reason to celebrate when there are children involved."
4 months ago
Sen. Bernie Sanders (I-Vt.) on Thursday released a tranche of Health and Human Services (HHS) emails that appear to show HHS Secretary Robert F. Kennedy Jr. pressuring the Centers for Disease Control and Prevention (CDC) over its vaccine messaging.
Emails indicate that Kennedy directed the CDC's vaccine advisory panel to restrict access to vaccines, allowed researchers to access "confidential data" to indicate the disproven claim that vaccines cause autism and changed recommendations for the public to receive COVID-19 shots without input from the CDC.
Other emails also show that Kennedy's then-chief of staff, Matthew Buckham, emailed former CDC Director Susan Monarez in August 2025 about the need for a "political review of major decisions at CDC … to ensure that [the Immediate Office of the Secretary] and the CDC political leadership all have eyes on the decisions for approval/changes before they go into effect."
Less than a week later, Kennedy fired Monarez "for failing to rubber stamp recommendations from" the CDC's vaccine panel, the Advisory Committee on Immunization Practices, Sanders said in a statement.
Sanders, the ranking member on the Senate Committee on Health, Education, Labor and Pensions (HELP), blasted Monarez's firing as "outrageous," accusing Kennedy of firing her "for her commitment to public health and vaccines." Sanders requested a bipartisan investigation into her firing and called on Kennedy to resign.
Emails indicate that Kennedy directed the CDC's vaccine advisory panel to restrict access to vaccines, allowed researchers to access "confidential data" to indicate the disproven claim that vaccines cause autism and changed recommendations for the public to receive COVID-19 shots without input from the CDC.
Other emails also show that Kennedy's then-chief of staff, Matthew Buckham, emailed former CDC Director Susan Monarez in August 2025 about the need for a "political review of major decisions at CDC … to ensure that [the Immediate Office of the Secretary] and the CDC political leadership all have eyes on the decisions for approval/changes before they go into effect."
Less than a week later, Kennedy fired Monarez "for failing to rubber stamp recommendations from" the CDC's vaccine panel, the Advisory Committee on Immunization Practices, Sanders said in a statement.
Sanders, the ranking member on the Senate Committee on Health, Education, Labor and Pensions (HELP), blasted Monarez's firing as "outrageous," accusing Kennedy of firing her "for her commitment to public health and vaccines." Sanders requested a bipartisan investigation into her firing and called on Kennedy to resign.
4 months ago
By Nate Raymond
BOSTON, June 18 (Reuters) - The Trump administration is urging a U.S. appeals court to overturn a ruling that blocked Health Secretary Robert F. Kennedy Jr.'s appointees from serving on a key vaccine advisory panel, saying the committee is unable to make annual recommendations on flu shots after a judge wrongly disabled it.
The U.S. Department of Justice made that argument in a brief filed late on Wednesday before the 1st U.S. Circuit Court of Appeals in its appeal of Boston-based U.S. District Judge Brian Murphy's March 16 ruling, which also blocked the panel from reducing the number of routinely recommended childhood vaccinations.
The Justice Department said it was not challenging that aspect of Murphy's ruling, meaning that the U.S. Centers for Disease Control and Prevention's January 5 move to cut the number of routinely recommended childhood vaccinations will remain on hold.
Nor is the administration challenging Murphy's decision to set aside other votes the CDC's Advisory Committee on Immunization Practices had taken under Kennedy's watch, including to downgrade recommendations for hepatitis B vaccines for newborns and COVID-19 shots broadly.
BOSTON, June 18 (Reuters) - The Trump administration is urging a U.S. appeals court to overturn a ruling that blocked Health Secretary Robert F. Kennedy Jr.'s appointees from serving on a key vaccine advisory panel, saying the committee is unable to make annual recommendations on flu shots after a judge wrongly disabled it.
The U.S. Department of Justice made that argument in a brief filed late on Wednesday before the 1st U.S. Circuit Court of Appeals in its appeal of Boston-based U.S. District Judge Brian Murphy's March 16 ruling, which also blocked the panel from reducing the number of routinely recommended childhood vaccinations.
The Justice Department said it was not challenging that aspect of Murphy's ruling, meaning that the U.S. Centers for Disease Control and Prevention's January 5 move to cut the number of routinely recommended childhood vaccinations will remain on hold.
Nor is the administration challenging Murphy's decision to set aside other votes the CDC's Advisory Committee on Immunization Practices had taken under Kennedy's watch, including to downgrade recommendations for hepatitis B vaccines for newborns and COVID-19 shots broadly.
4 months ago
Jennifer Lopez has declared she raised her twins Max and Emme with "very little help".
The Let's Get Loud diva opened up about the "crazy" journey of solo parenting her children, Emme and Max Muñiz, and explained how proud she was to have raised two two adults ready to go off to university.
"Now, I can really look at my life, appreciate it for what it is and what I've created for myself and be really happy," JLo, 56, told the SmartLess podcast.
"Both my kids got into all their colleges. They both got scholarships and they're going where they want to go."
She took a moment to congratulate herself on her own achievement, pointing out that for most of her children's lives, she had been a single mother.
"I was like, 'You did that s**t all by yourself,'" Jennifer explained to hosts Jason Bateman, Will Arnett and Sean Hayes. "That's great. Like, 'You had very little help,' you know?"
The Let's Get Loud diva opened up about the "crazy" journey of solo parenting her children, Emme and Max Muñiz, and explained how proud she was to have raised two two adults ready to go off to university.
"Now, I can really look at my life, appreciate it for what it is and what I've created for myself and be really happy," JLo, 56, told the SmartLess podcast.
"Both my kids got into all their colleges. They both got scholarships and they're going where they want to go."
She took a moment to congratulate herself on her own achievement, pointing out that for most of her children's lives, she had been a single mother.
"I was like, 'You did that s**t all by yourself,'" Jennifer explained to hosts Jason Bateman, Will Arnett and Sean Hayes. "That's great. Like, 'You had very little help,' you know?"
4 months ago
A proud family celebration turned into an emotional milestone for Jennifer Lopez as she watched her son Max Muniz graduate from high school.
Surrounded by loved ones, the singer and actress smiled for photos and embraced the moment, but it was clear something deeper was weighing on her mind.
With both of her children preparing for major life changes, Lopez found herself struggling to hold back tears.
Max Muniz marked a major chapter in his life when he graduated from high school during a ceremony held at UCLA.
The 18-year-old was surrounded by family members as he received his diploma, including his mother, twin sibling Oskar Muniz, grandparents Guadalupe and David Lopez, and Jennifer's longtime manager Benny Medina.
Surrounded by loved ones, the singer and actress smiled for photos and embraced the moment, but it was clear something deeper was weighing on her mind.
With both of her children preparing for major life changes, Lopez found herself struggling to hold back tears.
Max Muniz marked a major chapter in his life when he graduated from high school during a ceremony held at UCLA.
The 18-year-old was surrounded by family members as he received his diploma, including his mother, twin sibling Oskar Muniz, grandparents Guadalupe and David Lopez, and Jennifer's longtime manager Benny Medina.
9 months ago
U.S. vaccine panel chair questions polio recommendation for children
By Leah Douglas
WASHINGTON, Jan 23 (Reuters) - The chair of a U.S. government vaccine advisory panel questioned broad vaccine recommendations for polio and other childhood diseases and said promoting individual choice, not public health, is the key aim of the panel, drawing a rebuke on Friday from the nation's top doctors group.
Kirk Milhoan, a pediatric cardiologist who was named chair of the Centers for Disease Control and Prevention's outside Advisory Committee on Immunization Practices in December, made the comment
By Leah Douglas
WASHINGTON, Jan 23 (Reuters) - The chair of a U.S. government vaccine advisory panel questioned broad vaccine recommendations for polio and other childhood diseases and said promoting individual choice, not public health, is the key aim of the panel, drawing a rebuke on Friday from the nation's top doctors group.
Kirk Milhoan, a pediatric cardiologist who was named chair of the Centers for Disease Control and Prevention's outside Advisory Committee on Immunization Practices in December, made the comment
10 months ago
Trump directs RFK Jr. to review childhood vaccine plan after hepatitis B pivot
President Donald Trump is all in on Health Secretary Robert F. Kennedy Jr.’s plan to scrutinize the list of vaccines American children get.
Trump directed Kennedy on Friday to review the childhood vaccine schedule and potentially revise it to align with those of other developed countries, most of which recommend fewer shots.
The directive, in the form of an official presidential memo, was issued hours after federal vaccine advisers downgraded decades-old guidance urging newborn immunization against hepatitis B,
President Donald Trump is all in on Health Secretary Robert F. Kennedy Jr.’s plan to scrutinize the list of vaccines American children get.
Trump directed Kennedy on Friday to review the childhood vaccine schedule and potentially revise it to align with those of other developed countries, most of which recommend fewer shots.
The directive, in the form of an official presidential memo, was issued hours after federal vaccine advisers downgraded decades-old guidance urging newborn immunization against hepatitis B,
